FindTrial
Sign In

Understanding anti-TPO antibody levels in the thyroid disorder

Evaluation of anti-TPO enzyme in kaklak granthi dushti - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/09/073368
Enrollment
40
Registered
2024-09-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E078- Other specified disorders of thyroid

Interventions

None listed

Sponsors

NAVEENRAJ A
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients exhibiting the clinical features of Kaklak Granthi Dushti and Rasaprasodaja Vikara

Exclusion criteria

Exclusion criteria: Patients with smoking, alcohol, and other drug abuse are excluded. Patients with other systemic disorders like IBS, carcinoma, and other chronic autoimmune disorders like SLE, RA, etc., and infectious diseases like TB, and AIDS.

Design outcomes

Primary

MeasureTime frame
There will be an established relationship between the ANTI-TPO enzyme and pathogenesis generated in Kaklak Granthi Dushti patients.Timepoint: 7 to 15 hours—

Secondary

MeasureTime frame
ethiopathogenesis of kakalaka granthi dushti will be ruled outTimepoint: after 2 years—

Countries

India

Contacts

Public ContactDR Manjula K

KAHERs Shri B M Kankanawadi Ayurved Mahavidyalaya shahapur belagavi

nidan1819@gmail.com9844946360

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026